Best Peptides for Muscle Growth: The Complete Buyer’s Guide (2026)
If you’ve spent any time researching peptides for physique development, you’ve encountered a wall of conflicting information — forum speculation, outdated dosing protocols, and vendor marketing dressed up as science. This guide cuts through that noise.
We cover the five peptides most consistently associated with skeletal muscle hypertrophy and lean mass retention: CJC-1295, Ipamorelin, IGF-1 LR3, Hexarelin, and GHRP-6. For each, we explain the actual mechanism driving muscle growth, how it fits into a stack, training-specific dosing windows, and how it compares across effectiveness, cost, and risk profile.
Research Notice: All peptides discussed in this guide are research compounds. They are not approved by the FDA for muscle growth or performance enhancement. This content is for educational and informational purposes only — it does not constitute medical advice. Any use in humans requires oversight by a licensed physician. Consult a qualified healthcare provider before initiating any peptide protocol.
Why Peptides for Muscle Growth? The Biological Rationale
Skeletal muscle hypertrophy requires two things working in parallel: anabolic signaling (hormones and growth factors that trigger protein synthesis) and recovery capacity (cellular repair mechanisms that rebuild muscle fiber architecture after training stress).
Peptides target both pathways — primarily by amplifying the body’s endogenous growth hormone (GH) and IGF-1 axis. Here’s the cascade:
- GH is released from the anterior pituitary (either naturally or triggered by a GH secretagogue peptide)
- GH reaches the liver, which secretes Insulin-like Growth Factor-1 (IGF-1)
- IGF-1 binds to IGF-1R receptors on muscle cells, activating the PI3K/Akt/mTOR pathway
- mTOR activation drives muscle protein synthesis — the fundamental mechanism of hypertrophy
Some peptides (like IGF-1 LR3) bypass the GH step and directly stimulate IGF-1 receptors on muscle tissue, accelerating this cascade further downstream.
This is why GH peptides produce a distinct effect profile from anabolic steroids: they primarily work through hyperplasia (increasing satellite cell number and muscle fiber count) and enhanced protein synthesis signaling, with far less androgenic activity. The risk-to-reward calculus is therefore fundamentally different.
Quick Comparison Table
| Peptide | Primary Mechanism | Muscle Growth Potential | Side Effect Risk | Relative Cost | Best Use Case |
|---|---|---|---|---|---|
| CJC-1295 (no DAC) | GHRH analog → GH pulse | ★★★★☆ | Low | $$ | Foundation of any GH stack |
| Ipamorelin | Ghrelin mimetic → GH pulse | ★★★★☆ | Very Low | $$ | Paired with CJC-1295 for synergy |
| IGF-1 LR3 | Direct IGF-1R agonist | ★★★★★ | Moderate | $$$ | Advanced hypertrophy; post-workout |
| Hexarelin | GHRP → potent GH pulse | ★★★★★ | Moderate | $$ | Short cycles for maximum GH output |
| GHRP-6 | Ghrelin mimetic → GH pulse | ★★★★☆ | Low–Moderate | $ | Budget-accessible GH secretagogue |
Peptide #1: CJC-1295 (Without DAC)
Mechanism for Muscle Growth
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), modified at four amino acid positions to resist enzymatic degradation. It binds the GHRH receptor on pituitary somatotrophs and triggers a robust, physiologically-shaped GH pulse — typically producing a 3–5× increase over baseline GH levels within 15–30 minutes of injection.
For muscle growth, the value of CJC-1295 lies in its ability to consistently elevate GH pulsatility throughout a multi-week cycle. Sustained GH elevation drives chronic IGF-1 secretion from the liver, and it is this IGF-1 elevation — measured at the end of a 4–8 week cycle — that most researchers correlate with lean mass retention and hypertrophic response.
The “without DAC” (Drug Affinity Complex) designation is important. CJC-1295 without DAC (also called Modified GRF 1-29) has a half-life of approximately 30 minutes, producing a clean, natural-shaped pulse. The DAC-modified version has a multi-day half-life and produces prolonged, non-pulsatile GH elevation — which may blunt the body’s GH feedback mechanisms. For muscle growth purposes, the pulsatile version is generally preferred.
Dosing for Muscle Growth
Standard research dose: 100–300 mcg per injection
Frequency: 2–3× daily (most commonly before bed and pre-training)
Administration: Subcutaneous injection
Cycle length: 8–16 weeks; assess IGF-1 levels at 8-week mark
Training-day protocol:
- Pre-training injection: 100–200 mcg approximately 30–60 minutes before training, followed by a high-protein meal 45–60 minutes post-injection to leverage the GH-driven anabolic window
- Pre-sleep injection: 200–300 mcg at bedtime on an empty stomach (minimum 2 hours post-meal) — this amplifies the natural nocturnal GH surge that is the most anabolically significant pulse of the day
Key principle: Insulin blunts GH release. Meals — especially carbohydrate-heavy meals — should be timed away from CJC-1295 injections. The pre-sleep dose on an empty stomach consistently produces the largest GH pulse.
Side Effects
- Water retention — mild peripheral edema in first 2–4 weeks; usually resolves
- Joint discomfort — transient, related to fluid shifts; uncommon at standard doses
- Injection site irritation — mild redness, resolves within hours
- Headache — infrequent; typically mild
- Carpal tunnel-like symptoms — rare at standard doses; more common with higher doses or longer cycles
Cost & Sourcing
Estimated monthly cost: $150–$300 through research chemical suppliers (varies by dose and vendor)
CJC-1295 (no DAC) is widely available from established research peptide vendors and is among the most quality-consistent peptides in the market due to high demand and well-understood synthesis processes.
Peptide #2: Ipamorelin
Mechanism for Muscle Growth
Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2Nal-D-Phe-Lys-NH₂) that acts as a selective ghrelin receptor agonist — also called a growth hormone secretagogue receptor (GHSR) agonist. It stimulates the pituitary to release GH through a completely different receptor pathway than CJC-1295, which is the core reason these two peptides are almost always used together.
Where CJC-1295 works through the GHRH receptor, Ipamorelin works through the ghrelin receptor (GHS-R1a). When both receptors are activated simultaneously, the GH pulse produced is significantly greater than either peptide alone — this synergy is well-documented and is the pharmacological foundation of the ubiquitous CJC-1295 + Ipamorelin stack.
What makes Ipamorelin uniquely attractive for physique-focused researchers is its selectivity profile. Unlike GHRP-2 or GHRP-6, Ipamorelin does not meaningfully stimulate cortisol or prolactin — two hormones that are counterproductive to muscle growth and body composition. It also produces negligible appetite stimulation at standard doses, unlike GHRP-6.
For muscle growth: Ipamorelin contributes to the GH → IGF-1 cascade and has been shown to produce modest direct effects on osteoblast activity and lean mass when studied in animal models.
Dosing for Muscle Growth
Standard research dose: 100–300 mcg per injection
Frequency: 2–3× daily, always in combination with CJC-1295
Administration: Subcutaneous injection
Half-life: Approximately 2 hours
Training-day protocol (combined with CJC-1295):
- Pre-training: 100–200 mcg Ipamorelin + 100–200 mcg CJC-1295, 30–60 minutes before training, on an empty or low-carbohydrate stomach
- Pre-sleep: 200–300 mcg Ipamorelin + 200–300 mcg CJC-1295, on empty stomach before bed
These can be combined in the same syringe if both are reconstituted in bacteriostatic water at appropriate concentrations.
Side Effects
Ipamorelin has the most favorable side effect profile among all five peptides in this guide:
- Mild flushing or headache — brief, post-injection, resolves within 20–30 minutes
- Slight water retention — primarily mediated by GH effects, not the peptide directly
- Injection site reactions — uncommon
- No cortisol elevation — confirmed across multiple studies
- No prolactin elevation — confirmed; important distinction from older GHRPs
Cost & Sourcing
Estimated monthly cost: $150–$300 through research chemical vendors (often sold as a combined CJC-1295 / Ipamorelin stack at a slight discount)
Peptide #3: IGF-1 LR3
Mechanism for Muscle Growth
IGF-1 LR3 (Long Arg3 IGF-1) is structurally distinct from the other peptides in this guide. Rather than stimulating GH secretion from the pituitary, it acts as a direct agonist at the IGF-1 receptor (IGF-1R) on muscle, adipose, and connective tissue — effectively bypassing the GH-to-liver-to-IGF-1 step entirely.
The “LR3” modification (substituting arginine at position 3 and adding a 13-amino-acid N-terminal extension) dramatically reduces binding to IGF-binding proteins (IGFBPs) in the bloodstream. Normally, IGFBPs sequester a significant portion of circulating IGF-1, limiting its bioavailability at tissue receptors. By reducing IGFBP binding, IGF-1 LR3 has a half-life of 20–30 hours (versus 12–15 minutes for native IGF-1) and reaches skeletal muscle tissue with far greater efficiency.
The downstream effects for muscle growth are potent:
- Activation of the PI3K/Akt/mTOR pathway — the primary regulator of muscle protein synthesis
- Satellite cell proliferation — promotes muscle progenitor cell division, a key driver of true hyperplasia (increasing total muscle fiber number, not just size)
- Anti-catabolic effects — reduces muscle proteolysis, particularly useful in caloric deficits
- Nutrient partitioning — improves glucose uptake in skeletal muscle, directing calories toward muscle rather than fat tissue
IGF-1 LR3 is the only peptide in this guide capable of producing muscle hyperplasia (new fiber formation) rather than purely hypertrophy (fiber enlargement). This makes it uniquely valuable for researchers studying maximal lean mass accumulation.
Dosing for Muscle Growth
Standard research dose: 20–60 mcg per injection
Frequency: Once daily, post-training on training days; once daily in the morning on rest days
Administration: Subcutaneous or intramuscular injection
Cycle length: 4–6 weeks maximum; extended cycles risk IGF-1 receptor desensitization and hypoglycemia risk increases
Training-day protocol:
- Post-training injection: 40–60 mcg administered within 30 minutes of completing training, ideally alongside a high-protein, moderate-carbohydrate meal to leverage enhanced glucose disposal
- The post-training window is optimal because: (a) muscle IGF-1R upregulation is highest immediately post-exercise, (b) satellite cell activation is primed for proliferation signals, and (c) glucose uptake in muscle is enhanced, reducing hypoglycemia risk
Rest day protocol:
- 20–40 mcg in the morning with breakfast; lower dose than training days
Cycle structure: 4 weeks on, 4 weeks off minimum. Many researchers run 4-week cycles of IGF-1 LR3 on top of a longer 12–16 week CJC-1295 + Ipamorelin base.
Side Effects
IGF-1 LR3 carries a more significant risk profile than the GH secretagogue peptides:
- Hypoglycemia — the most serious risk; enhanced glucose uptake can cause blood sugar drops, particularly when injected fasted or in large doses. Always have fast-acting carbohydrates on hand
- Lethargy and fatigue — especially in the first 1–2 weeks as the body adjusts to enhanced glucose disposal
- Jaw pain / acromegalic symptoms — rare at standard doses but reported at higher doses; indicates excessive IGF-1 signaling
- Peripheral edema — fluid retention in extremities; dose-dependent
- Headaches — common in first week; usually resolves
- Increased mole/skin tag formation — possible with extended use; monitor skin
Cost & Sourcing
Estimated monthly cost: $200–$400 through research chemical vendors (higher cost per mg than GH secretagogues due to synthesis complexity)
Note: IGF-1 LR3 is one of the most commonly counterfeited research peptides. Quality verification through third-party testing (HPLC and MS certificates) is essential before use.
Peptide #4: Hexarelin
Mechanism for Muscle Growth
Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a hexapeptide GHRP — a growth hormone-releasing peptide that acts as a potent ghrelin receptor agonist. It is structurally related to GHRP-6 but produces substantially greater GH release, making it one of the most potent GH secretagogues identified in peptide research.
In head-to-head studies with other GHRPs, Hexarelin consistently demonstrates the highest GH peak amplitude — producing 5–10× baseline GH increases in some research protocols. For muscle growth, this potency translates to: stronger GH pulsatility, higher peak IGF-1 elevation over a cycle, and more pronounced effects on muscle protein synthesis signaling.
Hexarelin also has a unique cardiac effect not shared by other peptides in this guide. It binds to the CD36 receptor in cardiac tissue and has been studied for cardioprotective properties — including attenuation of cardiac fibrosis and protection against ischemic injury in animal models. While this is not directly relevant to muscle growth, it’s a notable secondary effect for researchers.
For physique-focused applications: Hexarelin is most commonly used in short, high-potency cycles (4–8 weeks) where the goal is maximum GH output — during aggressive lean mass phases or at the start of a longer GH peptide cycle before transitioning to the more sustainable CJC-1295 + Ipamorelin foundation.
Dosing for Muscle Growth
Standard research dose: 100–200 mcg per injection
Frequency: 1–3× daily
Administration: Subcutaneous injection
Half-life: Approximately 70 minutes
Cycle length: 4–8 weeks (desensitization occurs faster than with Ipamorelin — shorter cycles maintain response)
Training-day protocol:
- Pre-training: 100–200 mcg, 30–45 minutes before training. This times the GH peak with the training stimulus — the combination of exercise-induced GH secretion and exogenous GH peptide stimulation produces an additive GH pulse
- Pre-sleep (optional): 100 mcg at bedtime on an empty stomach to capture nocturnal GH pulse
Desensitization note: Unlike Ipamorelin, Hexarelin produces meaningful receptor desensitization with continuous twice-daily use beyond 8 weeks. Many researchers cycle Hexarelin 5 days on, 2 days off, or limit total cycle length to 6 weeks before cycling off or rotating to Ipamorelin.
Side Effects
- Cortisol elevation — moderate increase at standard doses; this is Hexarelin’s key liability for muscle growth applications, as elevated cortisol is catabolic and counterproductive
- Prolactin elevation — mild; more pronounced than Ipamorelin, less than GHRP-2
- Appetite stimulation — moderate; less than GHRP-6
- Water retention — moderate; GH-mediated
- Facial flushing — common, brief, post-injection
- Fatigue — reported by some researchers, particularly at higher doses
- Receptor desensitization — notable with continuous use; requires cycling
The cortisol elevation is Hexarelin’s most significant drawback for muscle growth. Many researchers mitigate this by co-administering phosphatidylserine (400–600 mg/day) or keeping cycle lengths short.
Cost & Sourcing
Estimated monthly cost: $100–$250 through research chemical vendors
Peptide #5: GHRP-6
Mechanism for Muscle Growth
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is one of the original synthetic ghrelin mimetics — a hexapeptide that binds the GHS-R1a receptor and was among the first GHRPs to be extensively characterized in clinical research. It produces a significant GH pulse (3–8× baseline depending on dose and individual GH axis sensitivity) and, importantly, does so with a well-established multi-decade research profile.
GHRP-6’s mechanism for muscle growth follows the same GH → IGF-1 → mTOR pathway as Ipamorelin and Hexarelin. Its distinguishing pharmacological feature is potent appetite stimulation — GHRP-6 significantly elevates ghrelin levels, which signals hunger through both central (hypothalamic) and peripheral pathways. In the context of a muscle-building phase where caloric surplus is the goal, this effect can be deliberately leveraged: the post-injection appetite window (typically 30–45 minutes post-dose) is an opportunity to consume a high-protein, calorie-dense meal in an anabolic context.
GHRP-6 has also demonstrated anti-inflammatory properties in animal models through liver protection (hepatoprotective effects mediated by the GHS-R1a receptor in hepatic tissue) — a secondary benefit relevant to researchers using oral medications or high training volumes.
Dosing for Muscle Growth
Standard research dose: 100–300 mcg per injection
Frequency: 2–3× daily
Administration: Subcutaneous injection
Half-life: Approximately 15–60 minutes (estimates vary across studies)
Training-day protocol:
- Pre-training: 100–200 mcg, 30–45 minutes before training, on an empty stomach. Use the appetite surge that follows training as the signal for a post-workout high-protein meal
- Pre-sleep: 200–300 mcg at bedtime, on an empty stomach. The appetite stimulation at this time is the main practical challenge — many researchers use the night dose on a schedule that allows 30–45 minutes of wakefulness post-injection before sleeping through the hunger window
Appetite management strategy: The hunger response is pronounced, predictable, and occurs 20–45 minutes post-injection. Timing GHRP-6 doses to precede planned meals (pre-training and around a large post-workout meal) converts this side effect into a functional advantage for researchers pursuing caloric surplus.
Side Effects
- Significant appetite stimulation — the defining side effect; can be advantageous or problematic depending on the goal
- Cortisol elevation — moderate; similar to Hexarelin, less pronounced than GHRP-2
- Prolactin elevation — mild to moderate
- Water retention — moderate; GH-mediated
- Lethargy — common in the first few weeks of use
- Facial flushing and warmth — brief post-injection
- Headache — mild, typically subsides with continued use
Cost & Sourcing
Estimated monthly cost: $60–$150 through research chemical vendors
GHRP-6 is the most affordable peptide on this list — it has been synthesized at scale for decades and is widely available from established vendors.
Recommended Stacks for Muscle Growth
Stack 1: The Foundation Stack (Beginner–Intermediate)
CJC-1295 (no DAC) + Ipamorelin
The most widely used GH peptide combination in research settings. Both peptides are GHRH-pathway and GHRP-pathway agonists respectively — activating complementary receptor systems for a synergistic GH pulse that exceeds either alone.
| Parameter | Protocol |
|---|---|
| CJC-1295 dose | 200 mcg |
| Ipamorelin dose | 200 mcg |
| Injection frequency | 2× daily (pre-training + pre-sleep) |
| Cycle length | 12–16 weeks |
| Rest days | Pre-sleep dose only |
Why this stack: Maximum GH stimulation with the lowest side effect burden in this category. Ipamorelin’s selectivity (no cortisol, no prolactin elevation) makes this a genuinely “clean” GH stimulus. Ideal for researchers prioritizing lean mass with minimal disruption to the cortisol/testosterone axis.
Expected outcomes at 12 weeks: Progressive IGF-1 elevation (typically 20–40% increase in serum IGF-1 over cycle), improved recovery between sessions, modest body recomposition (lean mass up, fat mass modestly reduced), improved sleep quality.
Stack 2: The Accelerated Hypertrophy Stack (Intermediate–Advanced)
CJC-1295 (no DAC) + Ipamorelin (base) + IGF-1 LR3 (pulse)
This stack layers direct IGF-1 receptor agonism on top of the GH-stimulating foundation, combining both mechanisms of action for a comprehensive approach to the GH/IGF-1 growth axis.
| Parameter | Protocol |
|---|---|
| CJC-1295 | 200 mcg, 2× daily (ongoing) |
| Ipamorelin | 200 mcg, 2× daily (ongoing) |
| IGF-1 LR3 | 40–60 mcg post-training (4-week pulses only) |
| IGF-1 LR3 cycle | 4 weeks on, 4 weeks off |
| Full stack duration | CJC-1295 + Ipa runs 16 weeks; IGF-1 LR3 runs weeks 1–4 and weeks 9–12 |
Hypoglycemia management (critical): Keep fast-acting carbohydrates (glucose tablets, fruit juice) accessible during IGF-1 LR3 administration weeks. Always inject post-training with food available. Do not inject fasted on rest days at the upper dose range.
Stack 3: The Maximum Output Stack (Advanced, Short Cycle)
Hexarelin + CJC-1295 (no DAC)
For researchers prioritizing maximum GH pulse amplitude over an 8-week lean mass cycle. Hexarelin replaces Ipamorelin here for its higher GH output, accepting the trade-off of moderate cortisol elevation.
| Parameter | Protocol |
|---|---|
| Hexarelin | 150 mcg, 2× daily |
| CJC-1295 | 200 mcg, 2× daily |
| Cycle length | 6–8 weeks maximum |
| Post-cycle | Transition to CJC-1295 + Ipamorelin for the continuation phase |
Cortisol mitigation: Phosphatidylserine (400 mg/day), taken with breakfast and dinner, has demonstrated cortisol attenuation in training contexts.
Stack 4: The Budget Stack (Beginner)
GHRP-6 + CJC-1295 (no DAC)
The most cost-accessible entry point into GH peptide research. GHRP-6 fills the GHRP role that Ipamorelin fills in the Foundation Stack — providing complementary receptor activation at significantly lower cost.
| Parameter | Protocol |
|---|---|
| GHRP-6 | 150–200 mcg, 2× daily |
| CJC-1295 | 200 mcg, 2× daily |
| Cycle length | 12 weeks |
| Key consideration | Plan meals around injection times to manage appetite stimulation |
Dosing Windows: Timing Peptides Around Training
The timing of GH peptide administration relative to training has a measurable impact on anabolic output. Here are the principles that govern optimal timing:
Principle 1: Insulin is the Enemy of GH Release
Elevated insulin — from any carbohydrate-containing meal — suppresses hypothalamic GHRH release and blunts pituitary GH output for 2–4 hours post-meal. Administer GH secretagogue peptides in a fasted or near-fasted state (minimum 2 hours post-carbohydrate meal) to allow unimpaired GH pulsatility.
The pre-sleep dose is most reliable for meeting this criterion — stomach is empty, insulin is low, and you’re capturing the body’s largest endogenous GH pulse.
Principle 2: Exercise Amplifies GH Peptide Response
Acute high-intensity exercise is itself a potent GH secretagogue. Administering a GH peptide 30–60 minutes before training creates an additive stimulus: the peptide-driven GH pulse coincides with exercise-induced GH release, producing a combined peak that exceeds either stimulus alone.
Recommended pre-training window: Inject 30–45 minutes before the first warm-up set. Avoid eating for 30 minutes post-injection minimum; then consume a high-protein meal approximately 45–60 minutes post-injection (timed to coincide with your post-workout meal).
Principle 3: IGF-1 LR3 Belongs Post-Training
Unlike GH secretagogues — which benefit from a pre-training injection — IGF-1 LR3 is optimally timed post-training:
- IGF-1 receptor density and sensitivity in skeletal muscle is highest in the 15–60 minutes immediately post-exercise
- Enhanced glucose disposal post-training reduces hypoglycemia risk from IGF-1 LR3
- Satellite cell activation is primed during the post-exercise recovery window, making IGF-1R stimulation maximally effective for hyperplasic signaling
Inject IGF-1 LR3 within 30 minutes of completing your last working set, alongside (or just before) a post-workout meal containing protein and moderate carbohydrates.
Principle 4: The Pre-Sleep Dose is Non-Negotiable
The most important GH pulse of the day occurs during the first 2 hours of slow-wave sleep — typically 60–90 minutes after falling asleep. Administering GH secretagogue peptides 20–30 minutes before sleep amplifies this pulse significantly.
Requirements for the pre-sleep dose:
- Empty stomach (2+ hours since last carbohydrate-containing meal)
- Maintain a consistent sleep schedule (irregular sleep disrupts GH pulsatility)
- Immediately after injection, avoid screen exposure and reduce ambient light to support sleep onset
Sample Training-Day Dosing Schedule
| Time | Action |
|---|---|
| 6:30 AM | Wake up (fasted) |
| 7:00 AM | Inject CJC-1295 200 mcg + Ipamorelin 200 mcg |
| 7:45–8:30 AM | Training session |
| 8:35 AM | [If using IGF-1 LR3]: Inject 40–60 mcg immediately post-training |
| 9:00 AM | High-protein post-workout meal (40–50g protein, moderate carbs) |
| 5:00–7:00 PM | Last carbohydrate-containing meal |
| 10:00 PM | Pre-sleep injection: CJC-1295 200–300 mcg + Ipamorelin 200–300 mcg (empty stomach) |
| 10:30 PM | Sleep |
Evaluating Quality: What to Look for in a Peptide Vendor
Research peptide quality varies enormously across vendors. Purity, accurate labeling, and sterile manufacturing are non-negotiable — and are not guaranteed by price alone. Here’s what to evaluate when sourcing:
Third-Party Testing
The non-negotiable minimum for any serious researcher. Look for vendors who publish COAs (Certificates of Analysis) from independent third-party laboratories, specifically:
- HPLC (High-Performance Liquid Chromatography) — confirms peptide purity and absence of related impurities
- Mass Spectrometry (MS) — confirms molecular identity (the peptide is what the vendor claims it is)
Any vendor unwilling to provide current COAs should be considered unsuitable regardless of other factors.
Manufacturing Standards
Reputable vendors disclose their manufacturing environment. Look for:
- Synthesized under sterile/cleanroom conditions
- GMP-adjacent or ISO-certified manufacturing partners
- Lyophilization (freeze-drying) completed in sterile environment
Indicators of Low-Quality Vendors
- No published third-party COAs (or COAs from non-verifiable labs)
- Price significantly below market (purity shortcuts are the most common cost-reduction mechanism)
- No clear contact information or customer service
- Claimed potency figures without supporting data
- Products that arrive at room temperature without desiccant
[Editor’s note: Affiliate vendor links — insert your verified, tested vendor recommendations here with your standard affiliate disclosure.]
Legal and Regulatory Status
All five peptides in this guide occupy the same regulatory category in the United States:
- CJC-1295, Ipamorelin, Hexarelin, GHRP-6, IGF-1 LR3: Not approved by the FDA for human use as performance enhancement or muscle growth agents. These are sold legally as research chemicals for in-vitro and animal research purposes.
- Purchasing for research purposes is legal in the United States and most other jurisdictions.
- IGF-1 LR3 in particular sits on WADA’s Prohibited List and the World Anti-Doping Code — relevant for competitive athletes subject to drug testing.
- Prescribers in clinical settings (anti-aging clinics, functional medicine) may legally prescribe compounded versions of some of these peptides (Ipamorelin, CJC-1295) under specific clinical indications. This is distinct from research chemical sourcing.
HelixVault provides educational content on peptide research. We do not encourage non-research use, provide medical advice, or recommend specific products for human administration.
Summary: Which Peptide Is Right for Your Research?
| Research Goal | Recommended Starting Point |
|---|---|
| New to peptide research; conservative approach | CJC-1295 + Ipamorelin (Foundation Stack) |
| Maximum lean mass accumulation | Foundation Stack + IGF-1 LR3 pulses (Advanced Stack) |
| Highest GH output, short cycle | Hexarelin + CJC-1295 (Maximum Output Stack) |
| Budget-accessible entry point | GHRP-6 + CJC-1295 (Budget Stack) |
| Anti-catabolic focus (cut/recomp) | IGF-1 LR3 alone (4-week cycle) + CJC-1295 + Ipamorelin base |
The through-line across all muscle growth peptide research: the GH/IGF-1 axis is the primary target, consistency beats intensity, and the pre-sleep dose is the most important variable in any protocol.
For researchers serious about the lean mass and physique applications, the CJC-1295 + Ipamorelin foundation is the appropriate starting point — it provides meaningful GH elevation with the lowest risk burden, runs cleanly over longer cycles, and creates the hormonal environment that supports the more advanced additions (IGF-1 LR3, Hexarelin) when and if a researcher’s protocol calls for them.
Related reading: Sermorelin vs. Ipamorelin vs. CJC-1295: Complete Comparison Guide | BPC-157 Complete Guide | Peptide Safety and Side Effects: The Complete Guide
Found this useful? Share it with someone who'd benefit.